MilliporeSigma Introduces Parteck M DPI

MilliporeSigma’s Parteck M DPI for dry powder inhalation (DPI) is a new grade of mannitol designed to improve flow and release characteristics of active pharmaceutical ingredients (APIs) in drugs delivered via dry, inhaled powders. Also, Parteck M DPI in dry powder inhalation formulations has the potential to improve compliance among patients who are lactose intolerant. According to the company, Parteck M DPI offers several advantages when compared with lactose, the only alternative carrier with associated pharmacopeia for dry powder inhalation.
           

Mannitol is chemically inert, has low moisture content and is a non-reducing sugar, making it suitable for formulation as it will not react with the API. Unlike lactose, which is derived from animal sources, Parteck M DPI is synthetic and manufactured with plant-based raw materials. 
           
Dry powder inhalation is an important pathway for drug delivery, and overcomes the challenges presented by aerosol formulations and nebulizers. Parteck M DPI helps to further improves dry powder formulations by addressing the shortcomings of lactose when used as a carrier.
           
Parteck M DPI will be incorporated into MilliporeSigma’s Emprove program, which provides online access to regulatory and technical information about the excipient and more than 400 other chemicals as well as filters and single-use components to help facilitate risk assessment and qualification processes.